Dan Carter carefully layered the sheets of tracing paper on the light box. On each sheet were renderings of the atomic components of an essential human protein, one whose structure had long been a mystery. With each layer Carter laid down, a never-before-seen image became clearer.

A surface rendering of the atomic structure of human serum albumin, illustrating charge distribution. NASA researchers at Marshall Space Flight Center were the first to map the atomic structure of albumin, an important blood protein.
Carter joined NASA’s Marshall Space Flight Center in 1985 and began exploring processes of protein crystal growth in space. By bouncing intense X-rays off the crystals, researchers can determine the electron densities around the thousands of atoms forming the protein molecules, unveiling their atomic structures. Cultivating crystals of sufficient quality on Earth was problematic; the microgravity conditions of space were far more accommodating. At the time, only a few hundred protein structures had been mapped, and the methods were time consuming and tedious. Carter hoped his work would help reveal the structure of human serum albumin, a major protein in the human circulatory system responsible for ferrying numerous small molecules in the blood.

More was at stake than scientific curiosity. “Albumin has a high affinity for most of the world’s pharmaceuticals,” Carter explains, “and its interaction with drugs can change their safety and efficacy.” When a medication enters the bloodstream—a cancer chemotherapy drug, for example—a majority of it can bind with albumin, leaving only a small percentage active for treatment. How a drug interacts with albumin can influence considerations like the necessary effective dosage, playing a significant role in the design and application of therapeutic measures.

In spite of numerous difficulties, including having no access to microgravity following the 1986 Space Shuttle Challenger disaster, the image Carter had hoped to see was finally clarifying. In 1988, his lab had acquired specialized X-ray and detection equipment—a tipping point. Carter and his colleagues began to piece together albumin’s portrait, the formation of its electron densities coalescing on the sheets of tracing paper he arranged on the light box. While space-grown crystals were ultimately not involved in the achievement, a year later, Carter says, “we were on the cover of Science magazine, having determined the atomic structure of albumin.”


The albumin mapping project began to reveal important aspects of how the protein bound with and transported drugs. After a number of years studying the formerly inscrutable molecule, it became apparent to Carter and a number of his colleagues that the potential of this knowledge to impact drug design and development was too great to ignore. In 1997, they founded New Century Pharmaceuticals Inc., based in Huntsville, Alabama, to launch a large-scale structural biology program to map at an atomic resolution the structures of drugs bound to albumin, with the intent to improve drug performance.

Over the following years, New Century continued to work with NASA through a series of grants and contracts in support of the Agency’s protein crystal growth in microgravity program. Several inventions discovered at NASA were also licensed to New Century so Carter and his team could continue to test and develop its albuminbased innovations. The company also developed a unique set of technologies based on the original albumin breakthrough.


New Century Pharmaceuticals Inc. has built upon the original NASA work on albumin to develop a new cancer drug combination approach that promises to improve anticancer drug performance and diminish the toxic side effects of chemotherapy.
Today, New Century’s Crystallography and Albuminbased Drug Design and Evaluation platform, or CADEX, is the world’s most extensive library of atomic structures demonstrating the binding characteristics of drugs and albumin. Covering over 25 therapeutic categories from antidepressants to anti-cancer agents to antihistamines, CADEX provides a comprehensive knowledge base for the development of drugs tailored to interact effectively with albumin.